Hallucinations

Microdose Is Pleased to Announce the DMT Conference: A Molecular Masterclass

Retrieved on: 
Tuesday, July 27, 2021

Toronto, Ontario--(Newsfile Corp. - July 27, 2021) - Microdose in partnership with Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, Algernon Pharmaceuticals Inc.  (CSE: AGN) a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and COVID-19, and Pharmadrug, a Biotech Company Focused on the R&D of Natural Based Medicines are pleased to announce the DMT Conference.

Key Points: 
  • The two-day virtual conference is to take place on September 9-10th 2021, starting at 12 pm EDT.
  • Join us as we take a scientific deep dive into the dynamic field of DMT therapeutics, with expert panels and engaging discussions.
  • Our Molecular Masterclasses are a speaker series designed for deep dives into the world's favourite psychoactive and psychedelic substances.
  • Each event will explore one drug, and feature a curated group of industry experts and thought leaders from around the world.

Tryp Therapeutics Appoints Robin Carhart-Harris, Ph.D. as SAB Chairman and Adds Daniel Clauw, M.D. as Scientific Advisor

Retrieved on: 
Monday, July 26, 2021

Dr. Carhart-Harris has published over 100 papers in peer-reviewed scientific journals and is one of the most cited researchers in the medical application of psychedelic compounds.

Key Points: 
  • Dr. Carhart-Harris has published over 100 papers in peer-reviewed scientific journals and is one of the most cited researchers in the medical application of psychedelic compounds.
  • Tryp is also announcing the appointment of Daniel Clauw, M.D., as a member of the Scientific Advisory Board.
  • We welcome their continued scientific leadership as we advance the development of our PFN program toward approved therapies for patients."
  • Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways.

Core One Labs’ Akome Seeks to Revolutionize Treatment of Parkinson’s Disease and Submits Application to Protect IP

Retrieved on: 
Monday, July 26, 2021

Akomes AKO004 psychedelic drug formulation, for use in the treatment of Parkinsons disease, is a composition comprising the psychedelic compound N,N-dimethyltryptamine (DMT) and, a specifically chosen, naturally occurring plant bioactive.

Key Points: 
  • Akomes AKO004 psychedelic drug formulation, for use in the treatment of Parkinsons disease, is a composition comprising the psychedelic compound N,N-dimethyltryptamine (DMT) and, a specifically chosen, naturally occurring plant bioactive.
  • 1It is estimated that over 10 million people worldwide are living with Parkinsons disease.
  • Within the United States it is further estimated that over 930,000 people live with Parkinsons disease and approximately 60,000 more are diagnosed each year.
  • Akomes AKO0004 drug formulation presents strong indication as a viable candidate for the treatment of Parkinsons disease, stated Joel Shacker CEO of the Company.

Mydecine Expands Portfolio of Novel Molecules Filing New Patent for MDMA-like Compounds

Retrieved on: 
Wednesday, July 21, 2021

At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds, said Rob Roscow, Chief Scientific Officer.

Key Points: 
  • At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds, said Rob Roscow, Chief Scientific Officer.
  • It is our belief that the tailoring of the properties of these compounds will vastly improve their utility to medicine and therapy.
  • The Companys goal is to continually add novel modifications to its portfolio of bespoke customizable features for psychedelic drugs to strengthen its IP portfolio.
  • The companys world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems.

Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness

Retrieved on: 
Wednesday, July 21, 2021

Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.

Key Points: 
  • Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.
  • Tryp will be collaborating with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School, a leading center in chronic pain research.
  • The upcoming Phase 2a trial is believed to be the world's first Phase 2 trial utilizing psilocybin for a chronic pain indication.
  • The clinical trial seeks to apply the neuroplasticity benefits of psilocybin to address the source of pain signals in fibromyalgia patients.

Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness

Retrieved on: 
Wednesday, July 21, 2021

NEW YORK, July 21, 2021 /PRNewswire/ -- The early 1970s saw psychedelics and psilocybin products made illegal in the US in the war on drugs. Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4%  and 20.6% of the adult population respectively. As psychedelics gain more recognition, companies such as Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF), Seelos Therapeutics (NASDAQ:SEEL), Numinus Wellness Inc. (TSXV:NUMI) (OTC:LKYSF), Mind Medicine (MindMed) (NASDAQ:MNMD) (NEO:MMED), and Mydecine Innovations Group Inc. (NEO:MYCO) (OTCPK:MYCOF) are engaging in research initiatives to develop psychedelic-assisted therapies for different mental illnesses and chronic pain conditions.

Key Points: 
  • Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.
  • Tryp will be collaborating with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School, a leading center in chronic pain research.
  • The upcoming Phase 2a trial is believed to be the world's first Phase 2 trial utilizing psilocybin for a chronic pain indication.
  • The clinical trial seeks to apply the neuroplasticity benefits of psilocybin to address the source of pain signals in fibromyalgia patients.

PSYC Launches Paid Media Partnership Services for Growing Medicinal Psychedelics Industry

Retrieved on: 
Tuesday, July 20, 2021

LAKE OSWEGO,OR, July 20, 2021 (GLOBE NEWSWIRE) -- Global Trac Solutions, Inc. (OTCPink: PSYC) (Global PSYC or the Company) a leading publicly traded digital media company within the emerging sector of medicinal psychedelics, is pleased to announce that the Company has begun the initial launch of its paid media partnership services that will be offered through its Psychedelic Spotlight platform and intended to be marketed to the growing number of companies within the emerging medicinal psychedelics industry.

Key Points: 
  • LAKE OSWEGO,OR, July 20, 2021 (GLOBE NEWSWIRE) -- Global Trac Solutions, Inc. (OTCPink: PSYC) (Global PSYC or the Company) a leading publicly traded digital media company within the emerging sector of medicinal psychedelics, is pleased to announce that the Company has begun the initial launch of its paid media partnership services that will be offered through its Psychedelic Spotlight platform and intended to be marketed to the growing number of companies within the emerging medicinal psychedelics industry.
  • The value opportunity that I believe this creates for PSYC is truly unique.
  • To coincide and contribute to the facilitation of the launch of these services, the Company has added Ms. Swati Sharma to its team as a Media Partnership Manager, and Mr. Greg Gilman as a Lead Copy Editor.
  • We support a harm reduction approach for the purpose of education and promoting individual and public safety.

Core One Labs to Present on its Proprietary Biosynthetic Psilocybin Technology at Investor Town Hall Event on August 4, 2021

Retrieved on: 
Sunday, July 18, 2021

The Virtual Town Hall event will comprise of a presentation by Dr. Hancock on the status of Vocans production of biosynthetic psilocybin and will include live video from the Companys operating laboratory in Victoria, British Columbia.

Key Points: 
  • The Virtual Town Hall event will comprise of a presentation by Dr. Hancock on the status of Vocans production of biosynthetic psilocybin and will include live video from the Companys operating laboratory in Victoria, British Columbia.
  • 2021 has been a significant year for Core One Labs, and our teams have been very focused on building a company that we truly feel sets precedent in the psychedelics space.
  • The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin.
  • Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients.

Psychedelic Science Leader Eleusis Announces Four New Board Appointments, Further Strengthening Leadership

Retrieved on: 
Monday, July 12, 2021

The new directors deep expertise building high-growth, high-impact life science companies complements Eleusiss world-class leadership team.

Key Points: 
  • The new directors deep expertise building high-growth, high-impact life science companies complements Eleusiss world-class leadership team.
  • This is an opportune moment for Eleusis to push forward its vision of transforming psychedelics into modern medicines, said David Socks, Chair of the board.
  • ELE-Psilo, the companys lead psychedelic drug candidate, is based on a proprietary, infusible form of psilocybin and is expected to enter clinical trials in early 2022.
  • David Socks currently serves on the board of directors of Phathom Pharmaceuticals (Nasdaq: PHAT), where he was the founding CEO through the companys IPO.

Psychedelic Decriminalization Creating Market Opportunities

Retrieved on: 
Monday, July 12, 2021

Legalization efforts began with marijuana in 2018, creating a booming market for investors.

Key Points: 
  • Legalization efforts began with marijuana in 2018, creating a booming market for investors.
  • Now, the psychedelics market is in the spotlight, with states across America looking to decriminalize psychedelic mushrooms.
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED)is a clinical-stage psychedelic medicine biotech company that develops psychedelic medicines and therapies for the treatment of mental illness and addiction.
  • COMP360, if approved, could receive up to 11 years of market exclusivity in the EU and US.